Phase-2 of a novel biologic agent to assess the effect of Eosinophil count in Asthma patients.

Study Name: RAINIER, Drug : Solrikitug. (Three Subcutaneous injections /once every 4 weeks). 

Total Study period: 28 days screening + 6months.

Inclusion criteria:

1. Age between 18-75
2. BMI between >18.5-<40 Kg/m2
3. Documented diagnosis of asthma 
4. On Dual or Triple therapy with medium or high dose ICS.
5. On a stable asthma medication for > 6 weeks

Exclusion:

1. Current smoker or quit smoking less than 6 months prior
2. Asthma exacerbation within 6 weeks

Please feel free to refer any candidates you come across in the clinic to Saira Saif or to Dr. Dania Shakaroun